Last reviewed · How we verify
BCD-236
BCD-236 is a small molecule that targets the PI3K/AKT pathway.
BCD-236 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | BCD-236 |
|---|---|
| Sponsor | Biocad |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
BCD-236 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. BCD-236 has shown promise in preclinical studies as a potential treatment for various cancers.
Approved indications
- Metastatic non-small cell lung cancer
- Metastatic breast cancer
Common side effects
- Diarrhea
- Nausea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |